Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Docusign Inc (DOCU) Price & Performance

Amgen, Inc.Trade
Docusign IncTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Docusign Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $225.71B), while Docusign Inc trades at $58.43 (market cap $11.39B). The key difference: Amgen, Inc. is far larger — about 19.8× Docusign Inc's market cap, and Amgen, Inc. pays a 2.42% dividend while Docusign Inc pays none. Which is the better fit depends on your goals.

AMGNDOCU
Market Cap
$225.71B$11.39B
Sector
HealthTechnology
52-Week High
$417.20$85.01
52-Week Low
$271.18$41.75
Enterprise Value
$269.02B$10.76B
Dividend Yield
2.42%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Docusign Inc

DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.

Read more on DOCU